<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2022-03-11T00:49:53Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8413007" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8413007</identifier>
        <datestamp>2021-09-03</datestamp>
        <setSpec>pheelsevier</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3-mathml3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Public Health</journal-id>
              <journal-id journal-id-type="iso-abbrev">Public Health</journal-id>
              <journal-title-group>
                <journal-title>Public Health</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0033-3506</issn>
              <issn pub-type="epub">1476-5616</issn>
              <publisher>
                <publisher-name>The Royal Society for Public Health. Published by Elsevier Ltd.</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8413007</article-id>
              <article-id pub-id-type="pmcid">PMC8413007</article-id>
              <article-id pub-id-type="pmc-uid">8413007</article-id>
              <article-id pub-id-type="pmid">34482101</article-id>
              <article-id pub-id-type="pii">S0033-3506(21)00307-3</article-id>
              <article-id pub-id-type="doi">10.1016/j.puhe.2021.07.037</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>The real-life impact of vaccination on COVID-19 mortality in Europe and Israel</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au1">
                  <name>
                    <surname>Jabłońska</surname>
                    <given-names>Katarzyna</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="cor1" ref-type="corresp">∗</xref>
                </contrib>
                <contrib contrib-type="author" id="au2">
                  <name>
                    <surname>Aballéa</surname>
                    <given-names>Samuel</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au3">
                  <name>
                    <surname>Toumi</surname>
                    <given-names>Mondher</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">c</xref>
                </contrib>
                <aff id="aff1"><label>a</label>Creativ-Ceutical, Ul. Przemysłowa 12, Kraków, 30-701, Poland</aff>
                <aff id="aff2"><label>b</label>Creativ-Ceutical, Westblaak 90, Rotterdam, 3012KM, the Netherlands</aff>
                <aff id="aff3"><label>c</label>Faculty of Medicine, Public Health Department, Aix-Marseille University, 27 Boulevard Jean Moulin, Marseille, 13005, France</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>∗</label>Corresponding author. Tel.: +33 17 670 47 90.</corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>3</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>3</day>
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <volume>198</volume>
              <fpage>230</fpage>
              <lpage>237</lpage>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>14</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>26</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>The Royal Society for Public Health</copyright-holder>
                <license>
                  <license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p>
                </license>
              </permissions>
              <abstract id="abs0010">
                <sec>
                  <title>Objectives</title>
                  <p>This study aimed at estimating the real-life impact of vaccination on COVID-19 mortality, with adjustment for SARS-CoV-2 variants spread and other factors across Europe and Israel.</p>
                </sec>
                <sec>
                  <title>Study design</title>
                  <p>Time series analysis.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>Time series analysis of the daily number of COVID-19 deaths was performed using non-linear Poisson mixed regression models. Variables such as variants’ frequency, demographics, climate, health, and mobility characteristics of thirty-two countries between January 2020 and April 2021 were considered as potentially relevant adjustment factors.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>The analysis revealed that vaccination efficacy in terms of protection against deaths was 72%, with a lower reduction of the number of deaths for B.1.1.7 vs non-B.1.1.7 variants (70% and 78%, respectively). Other factors significantly related to mortality were arrivals at airports, mobility change from the prepandemic level, and temperature.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>Our study confirms a strong effectiveness of COVID-19 vaccination based on real-life public data, although lower than expected from clinical trials. This suggests the absence of indirect protection for non-vaccinated individuals. Results also show that vaccination effectiveness against mortality associated with the B.1.1.7 variant is slightly lower than that with other variants. Lastly, this analysis confirms the role of mobility reduction, within and between countries, as an effective way to reduce COVID-19 mortality and suggests the possibility of seasonal variations in COVID-19 incidence.</p>
                </sec>
              </abstract>
              <kwd-group id="kwrds0010">
                <title>Keywords</title>
                <kwd>COVID-19 mortality</kwd>
                <kwd>SARS-CoV-2 variants</kwd>
                <kwd>B.1.1.7 variant</kwd>
                <kwd>VOC</kwd>
                <kwd>Vaccination</kwd>
                <kwd>Mobility</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="sec1">
              <title>Introduction</title>
              <p id="p0010">The pandemic of the coronavirus infectious disease 2019 (COVID-19) is continuously evolving, driven by the spread of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During the second half of 2020 and early 2021, a variety of new SARS-CoV-2 variants emerged. EU2 variant (mutation S:447N), first observed in July 2020 in Western Europe, was found to be capable of increasing virus infectivity.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>
<sup>,</sup>
<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Then, several variants of concern (VOCs) have been identified, including B.1.1.7 developed first in the UK in September 2020,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> B.1.351 in South Africa in December 2020,<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> P.1 in Brazil in January 2021,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> and the ‘Indian’ variant B.1.617 reported first in Maharashtra in January 2021.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> The disease mortality has been increased in these countries after new variants were developed.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref> An increased risk of transmissibility, hospitalization, and death associated with the B.1.1.7 variant was reported by a number of authors.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref>
<sup>,</sup>
<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref> The B.1.351 variant was found to have an increased transmissibility and immune escape<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> and was estimated to be 50% more transmissible than pre-existing variants.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Higher incidence of COVID-19 cases in younger age groups was observed in the Amazonas state, suggesting changes in pathogenicity of the P.1 variant.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Preliminary findings suggest also a significant increase in case fatality rate in young and middle-aged population for the P.1 mutant.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> The region of Maharashtra, where the B.1.617 variant emerged, experienced a significant rise in daily infection rate after the new variant appeared.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>
</p>
              <p id="p0015">To control the SARS-CoV-2 spread, a number of different vaccines have been developed and analyzed in clinical trials, including eight vaccines having emergency use or conditional marketing authorizations worldwide or across regions, as of May 2021.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> The worldwide vaccination campaign started in December 2020 aiming to provide herd immunity across societies. The threshold for COVID-19 ‘herd immunity’ was placed between 60 and 70% of the population gaining immunity through vaccinations or past disease exposure; however, scientists warn that herd immunity is unlikely to be achieved owing to factors such as vaccine hesitancy and the spread of new variants.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>
<sup>,</sup>
<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Israel was far ahead of other countries in terms of the proportion of vaccinated inhabitants, exceeding 62% at the end of April 2021, with the UK reaching 50% and the USA 42% at the same time.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref>
</p>
              <p id="p0020">Results of clinical trials on vaccine efficacy revealed that Pfizer-BioNTech had 95% efficacy at preventing symptomatic COVID-19 infection in people without prior infection.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Efficacy of 94.1% was reported for Moderna,<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> 70.4% for Oxford-AstraZeneca,<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> 66.5% for Johnson &amp; Johnson,<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> and 96.4% for Novavax,<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> with the latter being still under the investigation before authorization. For the prevention against a severe disease course, Pfizer, Moderna, AstraZeneca, and Novavax reported a 100% efficacy, whereas 84% was observed for Johnson &amp; Johnson; however, the latter was tested on a broader range of countries, including the USA, South Africa, and Brazil, after the new VOCs spread.</p>
              <p id="p0025">Clinical evidence suggests that newly developed virus variants may affect the protective efficacy of both naturally acquired immunity and vaccinations. Studies on neutralization of convalescent sera against distinct strains showed that VOCs were harder to neutralize than the original strain, an early Wuhan-related strain of SARS-CoV-2. Neutralization titers against the B.1.1.7 variant showed a threefold reduction,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> a 3.4-fold reduction was observed for the P.1 variant,<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> and a 13.3-fold reduction for the B.1.531 variant.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Johnson &amp; Johnson vaccine was found to have 64% efficacy against infection in South Africa and 68% in Brazil after the spread of B.1.135 and P.1 variants, whereas the efficacy against severe-critical disease was 82% and 88% in both countries.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Late March 2021, AstraZeneca was observed as having 70.4% efficacy against the B.1.1.7 variant;<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> however, the vaccine did not protect as well against the B.1.351 variant.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> For Novavax, the initial evidence suggests 86.3% efficacy against the B.1.1.7 variant<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> and 49.4% against the B.1.351 variant.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> Early May 2021, Pfizer vaccine was found to be 87% effective against infection with the B.1.1.7 variant and 72% against B.1.351 variant, whereas 97.4% efficacy against severe disease course was observed for any of these mutations.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> On the other hand, Wang et al.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> observed a reduced neutralization of Moderna and Pfizer vaccine-immune sera against the B.1.351 variant (12.4-fold for Moderna; 10.3-fold for Pfizer), but no significant impact was observed for the B.1.1.7 variant. Next, a 3.8- to 4.8-fold reduced neutralization of Moderna vaccine was observed against the P.1 variant.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Preliminary evidence suggests a significant drop in neutralization of B.1.617 compared with other variants, including B.1.1.7 and P.1, with sera of Indian's vaccine, Covaxine.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>
</p>
              <p id="p0030">The other concern is the probability of reinfection after recovery or vaccination. Hansen et al.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> observed an 80.5% protection against reinfection in a population-level observational study on Danish patients previously tested positive for SARS-CoV-2; however, the study was performed before VOCs spread. The probability of reinfection after vaccination is also a big concern. As reported by the US Centers for Disease Control and Prevention (CDC), there were around 9200 infections among vaccinated inhabitants among 95 million of those who have already been vaccinated in the USA (0.01%) as of 26 April 2021.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Despite these optimistic preliminary data, experts alarm that additional data are needed to assess the potential impact of VOCs on future vaccine efficacy.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Considering all the concerns associated with new VOC spread, the real vaccination effectiveness becomes hard to assess and judge but can be expected to decrease over time. Also, it is likely that vaccination may favor the emergence of new variants by selection of new, better fitted mutants. Some scientists suggest that, similarly as for seasonal flu vaccines, COVID-19 vaccines will need to be redesigned or even updated periodically to protect against new variants.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>
<sup>,</sup>
<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref>
</p>
              <p id="p0035">Vaccination efficacy and distinct variants spread are the only two factors among numerous other variables affecting COVID-19 infection and death rates across the world. A variety of potential predictors were assessed in the literature, including demographic characteristics, mobility and social-distancing measures, environmental and climate variables, as well as health characteristics.<xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref>
</p>
              <p id="p0040">This study aims at estimating the real-life impact of vaccination on COVID-19 mortality based on publicly available data from Europe and Israel, using time series analysis with non-linear mixed regression models. Variants frequency, including B.1.1.7 and other variants, as well as country-specific demographic and meteorological characteristics, health indicators, and mobility factors were considered as potentially relevant adjustment factors. Results of the current study should inform policy decision-makers, scientists, and the general public about the role of vaccination and social-distancing strategies in controlling the COVID-19 pandemic in the face of new VOCs spread.</p>
            </sec>
            <sec id="sec2">
              <title>Methods</title>
              <sec id="sec2.1">
                <title>Data collection</title>
                <p id="p0045">A total of 32 countries were considered in the analysis, including European countries and Israel. The daily number of COVID-19 deaths was the primary outcome of interest. Values were smoothed using 7-day moving average, divided by the number of inhabitants of a given country and reported as daily numbers of deaths per 1 million inhabitants.</p>
                <p id="p0050">The main explanatory variables of interest were proportion of vaccinated inhabitants (vaccination coverage), as well as average proportions of SARS-CoV-2 variants calculated across strains forming 12 Nextstrain clades. The focus was on 20A (EU2), 20E (EU1), and 20I (B.1.1.7) variants, with the two formers being dominant in Europe during the summer 2020 and the latter VOC being most frequent early 2021. Other time-varying covariates were maximum daily temperature, mean daily wind speed, the number of arrivals at two biggest airports of a country, and change in mobility from the prepandemic level (considering the average across retail/recreation, transit stations, and groceries/pharmacies). Additional fixed covariates were proportion of population aged 65 years or older, prevalence of diabetes, and rate of cardiovascular deaths.</p>
                <p id="p0055">Data on COVID-19 deaths and vaccination were obtained from Our World in Data on 15 April 2021.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Metadata on SARS-CoV-2 virus variants (clades) identified up to mid-April 2021 were downloaded from the Nextstrain platform.<xref rid="bib54" ref-type="bibr">54</xref>, <xref rid="bib55" ref-type="bibr">55</xref>, <xref rid="bib56" ref-type="bibr">56</xref> We assumed that if a strain was observed on a given date, it could be observed in a range of ±14 days from the observation date. Because the data were not reported daily, linear interpolation was used to impute missing observations, assuming zeros a month before the first and after the last (if up to 1 March 2021) reported occurrence of a variant. Finally, data were smoothed with the use of 14-day moving average.</p>
                <p id="p0060">Countries’ characteristics were obtained from Our World in Data, Eurostat, the National Centers for Environmental Information, Aviation Intelligence Portal, and Google COVID-19 Community Mobility Reports.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref>
<sup>,</sup>
<xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref>, <xref rid="bib59" ref-type="bibr">59</xref>, <xref rid="bib60" ref-type="bibr">60</xref> Data on arrival flights and mobility were smoothed using 7-day moving average.</p>
              </sec>
              <sec id="sec2.2">
                <title>Statistical analysis</title>
                <p id="p0065">Regression analysis was used to investigate the association between COVID-19 mortality and daily reported time-varying variables and fixed covariates.</p>
                <p id="p0070">The primary analysis of the daily number of COVID-19 deaths was performed with the use of non-linear Poisson mixed model with random country-level intercept and mobility effect. The considered period was from the date of the first reported death in Europe, 29 January 2020, up to 15 April 2021.</p>
                <p id="p0075">Owing to the presence of autocorrelations, and to consider the fact that the number of infections on a given day is dependent on the number of infectious cases in the population over previous days which translates into the respective number of deaths, the model was adjusted for the logarithm of the daily number of COVID-19 deaths reported 7 days earlier. To capture the fact that increasing or decreasing trends in COVID-19 mortality over time are generally stable over several weeks or months, the logarithm of quotient of COVID-19 deaths 7 days before divided by deaths 14 days before the actual date was added as a covariate. All other time-varying variables were considered with a 21-day lag, to account for the virus incubation period, assuming 7 days from contact to symptoms onset, and a delay between symptoms onset and death due to the disease, assuming another 14 days. In addition, heterogeneity between countries was considered with random intercepts and mobility effects varying between countries.</p>
                <p id="p0080">Assuming <italic>M</italic> indicates mortality with vaccination coverage ‘<italic>c</italic>’, <italic>M</italic>
<sub><italic>o</italic></sub> is the mortality without vaccination, and ‘<italic>VE</italic>’ represents the vaccine efficacy, we have:<disp-formula id="ufd1"><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mi>M</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:msub><mml:mi>M</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="goodbreak">⋅</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">−</mml:mo><mml:mi>c</mml:mi><mml:mo linebreak="badbreak">⋅</mml:mo><mml:mi>V</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>
</p>
                <p id="p0085">After applying the logarithmic transformation and considering a set of covariates <inline-formula><mml:math id="M2" altimg="si2.svg"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and random effects <inline-formula><mml:math id="M3" altimg="si3.svg"><mml:mrow><mml:msub><mml:mi>u</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mi>u</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> on intercept and selected <inline-formula><mml:math id="M4" altimg="si4.svg"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, this equation was extended as shown in the following to specify the non-linear model:<disp-formula id="ufd2"><mml:math id="M5" altimg="si5.svg"><mml:mrow><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">−</mml:mo><mml:mi>c</mml:mi><mml:mspace width="0.25em"/><mml:mo linebreak="badbreak">⋅</mml:mo><mml:mspace width="0.25em"/><mml:mi>V</mml:mi><mml:mi>E</mml:mi></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mo>…</mml:mo><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mo>…</mml:mo><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>
</p>
                <p id="p0090">For the exploratory analysis, vaccine efficacy against B.1.1.7 and non-B.1.1.7 variants was analyzed using a similar approach. Assuming that there are two classes of virus variants with known proportions equaled <inline-formula><mml:math id="M6" altimg="si6.svg"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M7" altimg="si7.svg"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, the vaccine efficacy could be considered as the average efficacy weighted by variants proportions:<disp-formula id="ufd3"><mml:math id="M8" altimg="si8.svg"><mml:mrow><mml:mi>V</mml:mi><mml:mi>E</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="goodbreak">⋅</mml:mo><mml:mi>V</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo linebreak="goodbreak">⋅</mml:mo><mml:mi>V</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>
</p>
                <p id="p0095">The formula for the non-linear model is then as follows:<disp-formula id="ufd4"><mml:math id="M9" altimg="si9.svg"><mml:mrow><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mi>M</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="badbreak">−</mml:mo><mml:mi>c</mml:mi><mml:mo linebreak="badbreak">⋅</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="badbreak">⋅</mml:mo><mml:mi>V</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo linebreak="badbreak">⋅</mml:mo><mml:mi>V</mml:mi><mml:msub><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mo>…</mml:mo><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo linebreak="badbreak">+</mml:mo><mml:mo>…</mml:mo><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>
</p>
                <p id="p0100">Additionally, three scenarios were tested as sensitivity analyses, varying either the time to symptoms onset or the time between symptoms onset and death. A detailed methodology is presented in <xref rid="appsec1" ref-type="sec">Supplementary Materials</xref>.</p>
                <p id="p0105">A <italic>P</italic>-value lower than 0.05 was considered as statistically significant. Akaike's information criterion (AIC) was provided to inform about models' fit statistic. Analyses were performed using SAS, version 9.4, software.</p>
              </sec>
            </sec>
            <sec id="sec3">
              <title>Results</title>
              <sec id="sec3.1">
                <title>Descriptive statistics</title>
                <p id="p0110">Descriptive statistics of outcomes and covariates across 32 countries included in the analysis, for the period between January 2020 and April 2021, are presented in <xref rid="tbl1" ref-type="table">Table 1</xref>
. Mean proportions of SARS-CoV-2 variants, EU2, EU1, and B.1.1.7, for each country are presented in <xref rid="fig1" ref-type="fig">Fig. 1</xref>
. Until mid-April 2021, the variant EU2 was the most frequently spread for vast majority of countries, except Israel and the UK for which B.1.1.7 was more frequent, as well as Spain and Lithuania with EU1 being more commonly observed.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Descriptive statistics of outcomes and covariates across 32 countries (January 2020–April 2021).</p></caption><alt-text id="alttext0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>N</th><th>Mean</th><th>Standard deviation</th><th>Median</th><th>Lower quartile</th><th>Upper quartile</th><th>Minimum</th><th>Maximum</th></tr></thead><tbody><tr><td>Number of daily COVID-19 deaths</td><td align="char">13,229</td><td align="char">3.355</td><td align="char">4.618</td><td align="char">1.159</td><td align="char">0.206</td><td align="char">4.933</td><td align="char">0</td><td align="char">28.770</td></tr><tr><td>Proportion of vaccinated inhabitants</td><td align="char">13,181</td><td align="char">0.018</td><td align="char">0.058</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0</td><td align="char">0.616</td></tr><tr><td>Proportion of 20A (EU2) variant</td><td align="char">13,106</td><td align="char">0.349</td><td align="char">0.250</td><td align="char">0.313</td><td align="char">0.154</td><td align="char">0.509</td><td align="char">0</td><td align="char">1.000</td></tr><tr><td>Proportion of 20E (EU1) variant</td><td align="char">12,754</td><td align="char">0.090</td><td align="char">0.159</td><td align="char">0</td><td align="char">0</td><td align="char">0.114</td><td align="char">0</td><td align="char">0.741</td></tr><tr><td>Proportion of 20I (B.1.1.7) variant</td><td align="char">13,099</td><td align="char">0.124</td><td align="char">0.256</td><td align="char">0</td><td align="char">0</td><td align="char">0.065</td><td align="char">0</td><td align="char">1.000</td></tr><tr><td>Max daily temperature</td><td align="char">13,008</td><td align="char">15.597</td><td align="char">9.347</td><td align="char">15.833</td><td align="char">8.750</td><td align="char">22.389</td><td align="char">−17.111</td><td align="char">43.111</td></tr><tr><td>Mean daily wind speed</td><td align="char">13,010</td><td align="char">6.227</td><td align="char">3.353</td><td align="char">5.600</td><td align="char">3.700</td><td align="char">8.100</td><td align="char">0.100</td><td align="char">25.800</td></tr><tr><td>Arrivals at two biggest airports</td><td align="char">12,748</td><td align="char">140.609</td><td align="char">195.648</td><td align="char">66.429</td><td align="char">27.714</td><td align="char">177.929</td><td align="char">1.857</td><td align="char">1780.143</td></tr><tr><td>Mobility change from prepandemic<xref rid="tbl1fna" ref-type="table-fn">a</xref></td><td align="char">12,918</td><td align="char">−0.217</td><td align="char">0.170</td><td align="char">−0.201</td><td align="char">−0.322</td><td align="char">−0.091</td><td align="char">−0.792</td><td align="char">0.199</td></tr><tr><td>Proportion of inhabitants aged ≥65 years</td><td align="char">13,229</td><td align="char">0.184</td><td align="char">0.025</td><td align="char">0.190</td><td align="char">0.168</td><td align="char">0.198</td><td align="char">0.117</td><td align="char">0.230</td></tr><tr><td>Diabetes prevalence</td><td align="char">13,229</td><td align="char">0.062</td><td align="char">0.019</td><td align="char">0.058</td><td align="char">0.048</td><td align="char">0.072</td><td align="char">0.033</td><td align="char">0.101</td></tr><tr><td>Cardiovascular death rate</td><td align="char">13,229</td><td align="char">2.037</td><td align="char">1.124</td><td align="char">1.535</td><td align="char">1.148</td><td align="char">2.783</td><td align="char">0.861</td><td align="char">5.398</td></tr></tbody></table><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Average mobility change from prepandemic level calculated across retail/recreation, transit stations, and groceries/pharmacies [0.01]. Descriptive statistics were calculated for 32 countries based on daily data between 29 January 2020 and 15 April 2021.</p></fn></table-wrap-foot></table-wrap><fig id="fig1"><label>Fig. 1</label><caption><p>Mean SARS-CoV-2 variants proportions across countries, between January 2020 and April 2021. Mean proportions of variants were calculated based on daily data on variants proportions across observed strains used to form Nextstrain clades (variants), between 29 January 2020 and 15 April 2021.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xlink:href="gr1_lrg"/></fig></p>
              </sec>
              <sec id="sec3.2">
                <title>Primary analysis</title>
                <p id="p0115">Analysis of the non-linear Poisson mixed model of the number of COVID-19 deaths revealed that the effect of vaccination effectiveness against mortality was assessed as significant and equaled to 0.720 (<italic>P</italic> &lt; 0.001; <xref rid="tbl2" ref-type="table">Table 2</xref>
). Other covariates that were found significant in the model were temperature (−0.005, <italic>P</italic> &lt; 0.001), arrivals at airports (0.709, <italic>P</italic> &lt; 0.001), and mobility change from the prepandemic level (0.753, <italic>P</italic> &lt; 0.001). Variables used to account for autocorrelation and minimize the effect of trend were assessed as significant (Log of the number of daily COVID-19 deaths 7 days before: 0.926, <italic>P</italic> &lt; 0.001; Log of the number of COVID-19 deaths 7 days before/14 days before: 0.158, <italic>P</italic> &lt; 0.010). The random intercept variance was statistically significant, which indicated significant unexplained variability between countries (0.014, <italic>P</italic> = 0.023).<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Results of the non-linear Poisson mixed model of the number of daily COVID-19 deaths.</p></caption><alt-text id="alttext0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Estimate</th><th>Standard error</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Intercept</td><td align="char">0.467</td><td align="char">0.202</td><td align="char">0.028</td></tr><tr><td>Logarithm of the number of daily COVID-19 deaths 7 days before<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td align="char">0.926</td><td align="char">0.007</td><td align="char">&lt;0.001</td></tr><tr><td>Logarithm of the number of COVID-19 deaths 7 days before/14 days before</td><td align="char">0.158</td><td align="char">0.015</td><td align="char">&lt;0.001</td></tr><tr><td>Proportion of 20A (EU2) variant<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char">0.012</td><td align="char">0.036</td><td align="char">0.746</td></tr><tr><td>Proportion of 20E (EU1) variant<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char">−0.032</td><td align="char">0.046</td><td align="char">0.501</td></tr><tr><td>Proportion of 20I (B.1.1.7) variant<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char">0.059</td><td align="char">0.033</td><td align="char">0.084</td></tr><tr><td>Max daily temperature<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char">−0.005</td><td align="char">0.001</td><td align="char">&lt;0.001</td></tr><tr><td>Mean daily wind speed<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char">−0.002</td><td align="char">0.002</td><td align="char">0.351</td></tr><tr><td>Arrivals at two biggest airports [in thousands]<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char">0.709</td><td align="char">0.085</td><td align="char">&lt;0.001</td></tr><tr><td>Mobility change from prepandemic<xref rid="tbl2fnb" ref-type="table-fn">b</xref>,<xref rid="tbl2fnd" ref-type="table-fn">d</xref></td><td align="char">0.753</td><td align="char">0.064</td><td align="char">&lt;0.001</td></tr><tr><td>Proportion of inhabitants aged ≥65 years<xref rid="tbl2fnc" ref-type="table-fn">c</xref></td><td align="char">−1.238</td><td align="char">0.930</td><td align="char">0.193</td></tr><tr><td>Diabetes prevalence<xref rid="tbl2fnc" ref-type="table-fn">c</xref></td><td align="char">0.544</td><td align="char">1.293</td><td align="char">0.677</td></tr><tr><td>Cardiovascular death rate<xref rid="tbl2fnc" ref-type="table-fn">c</xref></td><td align="char">0.023</td><td align="char">0.023</td><td align="char">0.322</td></tr><tr><td>Vaccination effectiveness<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td align="char">0.720</td><td align="char">0.132</td><td align="char">&lt;0.001</td></tr><tr><td><italic>Variance for RE on intercept</italic></td><td align="char">0.014</td><td align="char">0.006</td><td align="char">0.023</td></tr><tr><td><italic>Variance for RE on mobility</italic></td><td align="char">0.036</td><td align="char">0.023</td><td align="char">0.126</td></tr></tbody></table><table-wrap-foot><fn id="tspara0020"><p>AIC = 30,184.</p></fn><fn id="tspara0025"><p>Abbreviations: AIC = Akaike's information criterion; mln = million; RE = random effects.</p></fn><fn id="tspara0030"><p>Non-linear Poisson mixed model of the daily number of COVID-19 deaths per 1 mln inhabitants, with country-specific random effects on intercept and mobility. Daily data for 32 countries were included, from 29 January 2020 to 15 April 2021. Assumed time to symptoms onset is 7 days; assumed time between symptoms onset and death is 14 days.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p id="ntpara0015">Time-varying variable with a 7-days lag.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p id="ntpara0020">Time-varying variable with a 21-days lag.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnc"><label>c</label><p id="ntpara0025">Fixed variable.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnd"><label>d</label><p id="ntpara0030">Average mobility change from prepandemic level calculated across retail/recreation, transit stations, and groceries/pharmacies [0.01].</p></fn></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="sec3.3">
                <title>Exploratory analysis</title>
                <p id="p0120">Results of the analysis of the exploratory model revealed numerically lower vaccine effectiveness against B.1.1.7 than against non-B.1.1.7 variants, although the difference was not statistically significant (0.697, <italic>P</italic> = 0.002 and 0.778, <italic>P</italic> = 0.049, respectively; <xref rid="tbl3" ref-type="table">Table 3</xref>
). The same set of covariates was found significant in the exploratory model as in the primary analysis: temperature (−0.005, <italic>P</italic> &lt; 0.001), arrivals at airports (0.703, <italic>P</italic> &lt; 0.001), and mobility change from the prepandemic level (0.753, <italic>P</italic> &lt; 0.001). Variables used to account for autocorrelation and minimize the effect of trend were assessed as significant (Log of the number of daily COVID-19 deaths 7 days before: 0.926, <italic>P</italic> &lt; 0.001; Log of the number of COVID-19 deaths 7 days before/14 days before: 0.158, <italic>P</italic> &lt; 0.010), as was the variance for random intercept (0.013, <italic>P</italic> = 0.025).<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Results of the non-linear Poisson mixed model of the number of daily COVID-19 deaths with interactions between variants proportions and vaccination effectiveness.</p></caption><alt-text id="alttext0035">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Estimate</th><th>Standard error</th><th><italic>P</italic> value</th></tr></thead><tbody><tr><td>Intercept</td><td align="char">0.409</td><td align="char">0.204</td><td align="char">0.054</td></tr><tr><td>Logarithm of the number of daily COVID-19 deaths 7 days before<xref rid="tbl3fna" ref-type="table-fn">a</xref></td><td align="char">0.926</td><td align="char">0.007</td><td align="char">&lt;0.001</td></tr><tr><td>Logarithm of the number of COVID-19 deaths 7 days before/14 days before</td><td align="char">0.158</td><td align="char">0.015</td><td align="char">&lt;0.001</td></tr><tr><td>Proportion of 20A (EU2) variant<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="char">0.012</td><td align="char">0.036</td><td align="char">0.747</td></tr><tr><td>Proportion of 20E (EU1) variant<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="char">−0.034</td><td align="char">0.047</td><td align="char">0.467</td></tr><tr><td>Proportion of 20I (B.1.1.7) variant<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="char">0.059</td><td align="char">0.033</td><td align="char">0.085</td></tr><tr><td>Max daily temperature<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="char">−0.005</td><td align="char">0.001</td><td align="char">&lt;0.001</td></tr><tr><td>Mean daily wind speed<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="char">−0.002</td><td align="char">0.002</td><td align="char">0.346</td></tr><tr><td>Arrivals at two biggest airports [in thousands]<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="char">0.703</td><td align="char">0.085</td><td align="char">&lt;0.001</td></tr><tr><td>Mobility change from prepandemic<xref rid="tbl3fnb" ref-type="table-fn">b</xref>,<xref rid="tbl3fnd" ref-type="table-fn">d</xref></td><td align="char">0.753</td><td align="char">0.064</td><td align="char">&lt;0.001</td></tr><tr><td>Proportion of inhabitants aged ≥65 years<xref rid="tbl3fnc" ref-type="table-fn">c</xref></td><td align="char">−0.805</td><td align="char">0.925</td><td align="char">0.391</td></tr><tr><td>Diabetes prevalence<xref rid="tbl3fnc" ref-type="table-fn">c</xref></td><td align="char">0.124</td><td align="char">1.285</td><td align="char">0.924</td></tr><tr><td>Cardiovascular death rate<xref rid="tbl3fnc" ref-type="table-fn">c</xref></td><td align="char">0.025</td><td align="char">0.023</td><td align="char">0.278</td></tr><tr><td>Vaccination effectiveness against 20I (B.1.1.7)<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="char">0.697</td><td align="char">0.201</td><td align="char">0.002</td></tr><tr><td>Vaccination effectiveness against variants other than 20I (B.1.1.7)<xref rid="tbl3fnb" ref-type="table-fn">b</xref></td><td align="char">0.778</td><td align="char">0.379</td><td align="char">0.049</td></tr><tr><td><italic>Variance for RE on intercept</italic></td><td align="char">0.013</td><td align="char">0.006</td><td align="char">0.025</td></tr><tr><td><italic>Variance for RE on mobility</italic></td><td align="char">0.035</td><td align="char">0.023</td><td align="char">0.132</td></tr></tbody></table><table-wrap-foot><fn id="tspara0040"><p>AIC = 30,186.</p></fn><fn id="tspara0045"><p>Abbreviations: AIC = Akaike's information criterion; mln = million; RE = random effects.</p></fn><fn id="tspara0050"><p>Non-linear Poisson mixed model of the daily number of COVID-19 deaths per 1 mln inhabitants, with country-specific random effects on intercept and mobility, including interactions between variants proportions and vaccination effectiveness. Daily data for 32 countries were included, from 29 January 2020 to 15 April 2021. Assumed time to symptoms onset is 7 days; assumed time between symptoms onset and death is 14 days.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0035">Time-varying variable with a 7-days lag.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0040">Time-varying variable with a 21-days lag.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnc"><label>c</label><p id="ntpara0045">Fixed variable.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnd"><label>d</label><p id="ntpara0050">Average mobility change from prepandemic level calculated across retail/recreation, transit stations, and groceries/pharmacies [0.01].</p></fn></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="sec3.4">
                <title>Sensitivity analysis</title>
                <p id="p0125">Sensitivity analyses yielded overall vaccination effectiveness estimates against mortality between 0.60 and 0.72 (<xref rid="fig2" ref-type="fig">Fig. 2</xref>
). Regarding vaccination effectiveness associated with variants, two out of three scenarios provided consistent results with the main analysis, i.e., a trend towards lower effectiveness against the B.1.1.7 variant, and the opposite trend was observed in the remaining scenario (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). Detailed results are provided in <xref rid="appsec1" ref-type="sec">Supplementary Materials</xref>.<fig id="fig2"><label>Fig. 2</label><caption><p>Estimates of the vaccination effectiveness against mortality – main analysis and sensitivity analyses results. Abbreviations: 95% CI = 95% Confidence Interval. Assumptions of the analyses: Main analysis: time to onset = 7 days, time between symptoms onset and death = 14 days. Sensitivity analysis 1: time to onset = 14 days, time between symptoms onset and death = 14 days. Sensitivity analysis 2: time to onset = 14 days, time between symptoms onset and death = 7 days. Sensitivity analysis 3: time to onset = 7 days, time between symptoms onset and death = 7 days.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xlink:href="gr2_lrg"/></fig></p>
              </sec>
            </sec>
            <sec id="sec4">
              <title>Discussion</title>
              <p id="p0130">In this study, we investigated the association between daily mortality due to COVID-19 and vaccination coverage, proportions of SARS-CoV-2 variants, and additional factors, such as demographics, health, mobility, and meteorological variables, analyzing country-level data across Europe and Israel. Results of the analysis suggest that vaccination effectiveness against deaths is equal to 72% and that it is slightly lower against the B.1.1.7 variant than against non-B.1.1.7 variants (difference not statistically significant). These findings suggest lower effectiveness against death than reported efficacy against severe or critical disease course in clinical trials of vaccines (84–100%).<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>
</p>
              <p id="p0135">This lower-than-expected effectiveness might be explained by the difference in considered populations: clinical trials included restrictive populations, and our study covers general populations, irrespective of age, concomitant therapies, medical condition, and general condition. In particular, vaccinated people in real life are older on average than subjects enrolled in clinical trials (12.2% aged ≥55 years in the AstraZeneca trial; 24.7% aged ≥65 years in the Moderna trial; 33.5% aged ≥60 years in the Johnson &amp; Johnson trial; 42.3% aged ≥55 years in the Pfizer trial). However, our results suggesting lower protection against the B.1.1.7 variant are consistent with reported data so far from in vivo experiments and patient-level studies, providing an external validation of these findings. Laboratory evidence revealed a slight reduction in neutralization against the B.1.1.7 variant compared with the original strain. Neutralization titers against this VOC were threefold lower when analyzing convalescent sera and 3.3-fold and 2.5-fold lower for Pfizer and AstraZeneca vaccinees, respectively.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Real-world studies on the B.1.1.7 VOC suggested that it caused increased mortality compared with non-B.1.1.7 variants,<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref>
<sup>,</sup>
<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> which, therefore, might not have been contained with similar effectiveness by vaccination. Our results evoke the question of variants evading vaccine antibodies in the future and the need to adapt such vaccine for each new season, which was earlier suggested by experts.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref>
<sup>,</sup>
<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref>
</p>
              <p id="p0140">While the utilization of individual-level data, collected in real-world setting, could provide more precise estimates of vaccine effectiveness, the use of aggregate data at country level also has a major advantage: the vaccination impact estimated in this analysis should capture the indirect protection provided by vaccination. If the vaccine protects against infection, the number of infectious cases would decrease as more people are vaccinated. The lower number of infectious cases in the population would lead to a reduced probability for susceptible individuals to get in contact with infectious cases, thus leading to a reduction in incidence among all people, including non-vaccinated people. This indirect protection can be captured when comparing different populations with different rates of vaccination coverage, but could not be captured when comparing vaccinated and non-vaccinated individuals from the same population. Interestingly, the fact that our estimated vaccine effectiveness is relatively low compared with vaccine efficacy reported in clinical trials suggests that there is no or little indirect protection provided by vaccination. This could indicate that the vaccine protects against disease but not against infection or that vaccinated groups of population are not those that contribute to the propagation of the virus.</p>
              <p id="p0145">A positive relationship between the number of arrivals at airports and mortality has been observed in this analysis, similarly as between mobility change and mortality. It suggests that both increased long-distance travel and increased mobility are strong predictors of growth in the daily number of COVID-19 deaths. These findings highlight the role of mobility reduction, both within and between countries, as an effective way to reduce COVID-19 mortality, especially when new virus variants spread across the world. Our results are in line with previous study by Jabłońska et al.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> suggesting that countries with lower reduction in mobility at the beginning of the pandemic experienced a higher COVID-19 daily deaths peak. The role of social distancing was also underlined by Badr et al.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref> who observed a significant impact of mobility on COVID-19 transmission in the USA.</p>
              <p id="p0150">The daily temperature was found as a significant predictor of COVID-19 mortality in this study, with increasing temperature associated with the reduction in the number of deaths. Kerr et al.<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> found no consensus on the impact of meteorological factors on COVID-19 spread in their literature review; however, they suggested existence of environmental sensitivity of COVID-19, but not as significant as non-pharmaceutical interventions and human behavior. Several authors underlined that disease seasonality may exist,<xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref>, <xref rid="bib66" ref-type="bibr">66</xref>, <xref rid="bib67" ref-type="bibr">67</xref> including Liu et al.<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> who found that COVID-19 infection and mortality rates were higher in colder climates and that the cold season caused an increase in total infections, while the warm season contributed to the opposite effect. Because our analysis covered a full annual cycle of COVID-19, our result suggests the possibility of seasonal variations in COVID-19 incidence. Such seasonality has been well established in temperate climate for other respiratory viruses.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref>
<sup>,</sup>
<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref>
</p>
              <sec id="sec4.1">
                <title>Limitations</title>
                <p id="p0155">Our study has several limitations. First, our analysis was conducted on a country-level basis to estimate the vaccination efficacy, which should be seen as a less precise method than analysis of individual-level data, as previously noted. However, given the range of included countries, our results shed light on the problem of vaccination effectiveness from a broader perspective and investigate the effect of vaccination across societies, considering variability of vaccination coverage through time and between countries. Second, the quality of data on variants distribution varied between countries and was low for some of them; therefore, results of the exploratory analysis should be treated with cautious. To limit bias and avoid fluctuations, we used methods of interpolation and smoothing. Countries with limited data were excluded. Third, the set of covariates used in the multivariate analysis can be assessed as non-exhaustive. We decided to consider factors that were previously assessed as significantly impacting the risk of severe illness or mortality from COVID-19 in the literature.<xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib49" ref-type="bibr">49</xref>, <xref rid="bib50" ref-type="bibr">50</xref>, <xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref>, <xref rid="bib53" ref-type="bibr">53</xref> Also, the significant random intercept observed in our models reflects unexplained between-countries variability resulting from the omission of influential variables. It was previously shown, for example, that COVID-19 mortality may be influenced by economic factors, which were not considered in this analysis.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> Finally, we were not able to consider other new SARS-CoV-2 VOCs, except B.1.1.7, in the current analysis, which was due to their limited spread in Europe as of April 2021. It rises a need for further research on this topic in the future.</p>
              </sec>
              <sec id="sec4.2">
                <title>Conclusions</title>
                <p id="p0160">This study confirms a strong effectiveness of COVID-19 vaccination based on real-life public data, in terms of protection against deaths being around 72%, although it appears to be slightly lower than could be expected from clinical trial results. This suggests the absence of indirect protection for non-vaccinated individuals. Results also suggest that vaccination effectiveness against mortality associated with the B.1.1.7 variant is high but slightly lower than other variants (70% and 78%, respectively). Finally, this analysis confirms the role of mobility reduction, both within and between countries, as an effective way to reduce COVID-19 mortality and supports the possibility of seasonal variations in COVID-19 incidence.</p>
              </sec>
            </sec>
            <sec id="sec5">
              <title>Author statements</title>
              <sec id="sec5.1">
                <title>Ethical approval</title>
                <p id="p0165">Not required. This study does not require ethical approval as it was conducted on country-level data and involved information freely available in the public domain.</p>
              </sec>
              <sec id="sec5.2">
                <title>Funding</title>
                <p id="p0170">None. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.</p>
              </sec>
              <sec id="sec5.3">
                <title>Competing interests</title>
                <p id="p0175">None declared.</p>
              </sec>
              <sec id="sec5.4">
                <title>Contributors</title>
                <p id="p0180">MT conceptualized the study. KJ and SA validated the study concept. KJ and SA collected and analyzed the data. KJ, SA, and MT interpreted the results. KJ wrote the first draft of the manuscript. KJ, SA, and MT revised the manuscript and approved the final version.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <label>1</label>
                <element-citation publication-type="journal" id="sref1">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>VanBlargan</surname>
                      <given-names>L.A.</given-names>
                    </name>
                    <name>
                      <surname>Rothlauf</surname>
                      <given-names>P.W.</given-names>
                    </name>
                    <name>
                      <surname>Bloyet</surname>
                      <given-names>L.-M.</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>R.E.</given-names>
                    </name>
                    <name>
                      <surname>Stumpf</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization</article-title>
                  <source>bioRxiv</source>
                  <year>2020</year>
                  <comment>2020.11.06.372037</comment>
                </element-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <element-citation publication-type="book" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hodcroft</surname>
                      <given-names>E.B.</given-names>
                    </name>
                  </person-group>
                  <part-title>CoVariants: SARS-CoV-2 mutations and variants of interest</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://covariants.org/" id="intref0015">https://covariants.org/</ext-link>
                </element-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <mixed-citation publication-type="other" id="sref3">Rambaut A, Loman N, Pybus O. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563" id="intref0020">https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563</ext-link> (accessed 15th March 2021).</mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tegally</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Wilkinson</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Giovanetti</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Iranzadeh</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Fonseca</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Giandhari</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa</article-title>
                  <source>medRxiv</source>
                  <year>2020</year>
                  <fpage>2020</fpage>
                  <comment>12.21.20248640</comment>
                </element-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <element-citation publication-type="book" id="sref5">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Faria</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Claro</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Candido</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Franco</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Andrade</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Coletti</surname>
                      <given-names>T.</given-names>
                    </name>
                  </person-group>
                  <part-title>Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586" id="intref0025">https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586</ext-link>
                </element-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <element-citation publication-type="book" id="sref6">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Barnagarwala</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Mascarenhas</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <part-title>Explained: B.1.617 variant and the Covid-19 surge in India</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://indianexpress.com/article/explained/maharashtra-double-mutant-found-b-1-617-variant-and-the-surge-7274080/" id="intref0030">https://indianexpress.com/article/explained/maharashtra-double-mutant-found-b-1-617-variant-and-the-surge-7274080/</ext-link>
                </element-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <element-citation publication-type="book" id="sref7">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Naveca</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>da Costa</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Nascimento</surname>
                      <given-names>V.</given-names>
                    </name>
                  </person-group>
                  <part-title>SARS-CoV-2 reinfection by the new variant of concern (VOC) P.1 in Amazonas, Brazil</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596" id="intref0035">https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596</ext-link>
                </element-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <element-citation publication-type="journal" id="sref8">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Iacobucci</surname>
                      <given-names>G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Covid-19: new UK variant may be linked to increased death rate, early data indicate</article-title>
                  <source>BMJ</source>
                  <volume>372</volume>
                  <year>2021</year>
                  <fpage>n230</fpage>
                  <pub-id pub-id-type="pmid">33500262</pub-id>
                </element-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jassat</surname>
                      <given-names>W.</given-names>
                    </name>
                    <name>
                      <surname>Mudara</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Ozougwu</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Tempia</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Blumberg</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Davies</surname>
                      <given-names>M.-A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa</article-title>
                  <source>Lancet Glob Health</source>
                  <volume>9</volume>
                  <issue>9</issue>
                  <year>2021</year>
                  <fpage>e1216</fpage>
                  <lpage>e1225</lpage>
                  <pub-id pub-id-type="pmid">34252381</pub-id>
                </element-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <element-citation publication-type="journal" id="sref10">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yadav</surname>
                      <given-names>P.D.</given-names>
                    </name>
                    <name>
                      <surname>Sapkal</surname>
                      <given-names>G.N.</given-names>
                    </name>
                    <name>
                      <surname>Abraham</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Ella</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Deshpande</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Patil</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees</article-title>
                  <source>Clin Infect Dis</source>
                  <year>2021 May 7</year>
                  <pub-id pub-id-type="doi">10.1093/cid/ciab411</pub-id>
                  <comment>ciab411. Epub ahead of print</comment>
                </element-citation>
              </ref>
              <ref id="bib11">
                <label>11</label>
                <element-citation publication-type="journal" id="sref11">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wallace</surname>
                      <given-names>D.J.</given-names>
                    </name>
                    <name>
                      <surname>Ackland</surname>
                      <given-names>G.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Abrupt increase in the UK coronavirus death-case ratio in December 2020</article-title>
                  <source>medRxiv</source>
                  <year>2021</year>
                  <comment>2021.01.21.21250264</comment>
                </element-citation>
              </ref>
              <ref id="bib12">
                <label>12</label>
                <element-citation publication-type="journal" id="sref12">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Challen</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Brooks-Pollock</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Read</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Dyson</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Tsaneva-Atanasova</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Danon</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study</article-title>
                  <source>BMJ</source>
                  <volume>372</volume>
                  <year>2021</year>
                  <fpage>n579</fpage>
                  <pub-id pub-id-type="pmid">33687922</pub-id>
                </element-citation>
              </ref>
              <ref id="bib13">
                <label>13</label>
                <element-citation publication-type="book" id="sref13">
                  <person-group person-group-type="author">
                    <collab>New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG)</collab>
                  </person-group>
                  <part-title>Resport to SAGE: increased disease severity in people infected with variant of concern (VOC) B.1.1.7 compared to people infected with non-VOC virus variants</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf" id="intref0040">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/961042/S1095_NERVTAG_update_note_on_B.1.1.7_severity_20210211.pdf</ext-link>
                </element-citation>
              </ref>
              <ref id="bib14">
                <label>14</label>
                <element-citation publication-type="book" id="sref14">
                  <person-group person-group-type="author">
                    <collab>Public Health England</collab>
                  </person-group>
                  <part-title>SARS-CoV-2 variants of concern and variants under investigation in England</part-title>
                  <year>2021</year>
                  <comment>Technical briefing 7. 11th March</comment>
                  <ext-link ext-link-type="uri" xlink:href="https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201" id="intref0045">https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201</ext-link>
                  <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/968581/Variants_of_Concern_VOC_Technical_Briefing_7_England.pdf" id="intref0050">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/968581/Variants_of_Concern_VOC_Technical_Briefing_7_England.pdf</ext-link>
                </element-citation>
              </ref>
              <ref id="bib15">
                <label>15</label>
                <element-citation publication-type="journal" id="sref15">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>N.G.</given-names>
                    </name>
                    <name>
                      <surname>Jarvis</surname>
                      <given-names>C.I.</given-names>
                    </name>
                    <name>
                      <surname>van Zandvoort</surname>
                      <given-names>K.</given-names>
                    </name>
                    <collab>CMMID COVID-19 Working Group</collab>
                    <name>
                      <surname>Edmunds</surname>
                      <given-names>W.J.</given-names>
                    </name>
                    <name>
                      <surname>Jewell</surname>
                      <given-names>N.P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7</article-title>
                  <source>Nature</source>
                  <volume>593</volume>
                  <year>2021</year>
                  <fpage>270</fpage>
                  <lpage>274</lpage>
                  <pub-id pub-id-type="pmid">33723411</pub-id>
                </element-citation>
              </ref>
              <ref id="bib16">
                <label>16</label>
                <element-citation publication-type="journal" id="sref16">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Davies</surname>
                      <given-names>N.G.</given-names>
                    </name>
                    <name>
                      <surname>Abbott</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Barnard</surname>
                      <given-names>R.C.</given-names>
                    </name>
                    <name>
                      <surname>Jarvis</surname>
                      <given-names>C.I.</given-names>
                    </name>
                    <name>
                      <surname>Kucharski</surname>
                      <given-names>A.J.</given-names>
                    </name>
                    <name>
                      <surname>Munday</surname>
                      <given-names>J.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England</article-title>
                  <source>Science</source>
                  <volume>372</volume>
                  <issue>6538</issue>
                  <year>2021</year>
                  <comment>eabg3055</comment>
                </element-citation>
              </ref>
              <ref id="bib17">
                <label>17</label>
                <element-citation publication-type="journal" id="sref17">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tegally</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Wilkinson</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Giovanetti</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Iranzadeh</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Fonseca</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Giandhari</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Detection of a SARS-CoV-2 variant of concern in South Africa</article-title>
                  <source>Nature</source>
                  <volume>592</volume>
                  <issue>7854</issue>
                  <year>2021</year>
                  <fpage>438</fpage>
                  <lpage>443</lpage>
                  <pub-id pub-id-type="pmid">33690265</pub-id>
                </element-citation>
              </ref>
              <ref id="bib18">
                <label>18</label>
                <element-citation publication-type="book" id="sref18">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pearson</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Russell</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Davies</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Kucharski</surname>
                      <given-names>A.</given-names>
                    </name>
                    <collab>CMMID COVID-19 working group</collab>
                    <name>
                      <surname>Edmunds</surname>
                      <given-names>W.</given-names>
                    </name>
                  </person-group>
                  <part-title>Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa</part-title>
                  <year>2021</year>
                  <publisher-name>Centre for Mathematical Modelling of Infectious Diseases</publisher-name>
                  <ext-link ext-link-type="uri" xlink:href="https://cmmid.github.io/topics/covid19/sa-novel-variant.html" id="interref0010">https://cmmid.github.io/topics/covid19/sa-novel-variant.html</ext-link>
                </element-citation>
              </ref>
              <ref id="bib19">
                <label>19</label>
                <element-citation publication-type="book" id="sref19">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Freitas</surname>
                      <given-names>A.R.R.</given-names>
                    </name>
                    <name>
                      <surname>Beckedorff</surname>
                      <given-names>O.A.</given-names>
                    </name>
                    <name>
                      <surname>de Góes Cavalcanti</surname>
                      <given-names>L.P.</given-names>
                    </name>
                    <name>
                      <surname>Siqueira</surname>
                      <given-names>A.M.</given-names>
                    </name>
                    <name>
                      <surname>Castro</surname>
                      <given-names>D.B.</given-names>
                    </name>
                    <name>
                      <surname>Costa</surname>
                      <given-names>C.F.D.</given-names>
                    </name>
                  </person-group>
                  <part-title>The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and gender profile of COVID-19 mortality</part-title>
                  <year>2021</year>
                </element-citation>
              </ref>
              <ref id="bib20">
                <label>20</label>
                <element-citation publication-type="journal" id="sref20">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Oliveira</surname>
                      <given-names>M.H.S.</given-names>
                    </name>
                    <name>
                      <surname>Lippi</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Henry</surname>
                      <given-names>B.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Sudden rise in COVID-19 case fatality among young and middle-aged adults in the south of Brazil after identification of the novel B.1.1.28.1 (P.1) SARS-CoV-2 strain: analysis of data from the state of Parana</article-title>
                  <source>medRxiv</source>
                  <year>2021</year>
                  <comment>2021.03.24.21254046</comment>
                </element-citation>
              </ref>
              <ref id="bib21">
                <label>21</label>
                <element-citation publication-type="book" id="sref21">
                  <person-group person-group-type="author">
                    <collab>The New York Times</collab>
                  </person-group>
                  <part-title>Coronavirus vaccine tracker</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html" id="intref0055">https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html</ext-link>
                </element-citation>
              </ref>
              <ref id="bib22">
                <label>22</label>
                <element-citation publication-type="book" id="sref22">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Aschwanden</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <part-title>Five reasons why COVID herd immunity is probably impossible</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41586-021-00728-2" id="intref0060">https://www.nature.com/articles/d41586-021-00728-2</ext-link>
                </element-citation>
              </ref>
              <ref id="bib23">
                <label>23</label>
                <element-citation publication-type="book" id="sref23">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gu</surname>
                      <given-names>Y.</given-names>
                    </name>
                  </person-group>
                  <part-title>Path to normality: 2021 outlook of COVID-19 in the US</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://covid19-projections.com/path-to-herd-immunity/" id="intref0065">https://covid19-projections.com/path-to-herd-immunity/</ext-link>
                </element-citation>
              </ref>
              <ref id="bib24">
                <label>24</label>
                <element-citation publication-type="book" id="sref24">
                  <source>Our world in data. Coronavirus (COVID-19) vaccinations</source>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://ourworldindata.org/covid-vaccinations" id="intref0070">https://ourworldindata.org/covid-vaccinations</ext-link>
                </element-citation>
              </ref>
              <ref id="bib25">
                <label>25</label>
                <element-citation publication-type="journal" id="sref25">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Polack</surname>
                      <given-names>F.P.</given-names>
                    </name>
                    <name>
                      <surname>Thomas</surname>
                      <given-names>S.J.</given-names>
                    </name>
                    <name>
                      <surname>Kitchin</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Absalon</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Gurtman</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Lockhart</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title>
                  <source>N Engl J Med</source>
                  <volume>383</volume>
                  <issue>27</issue>
                  <year>2020</year>
                  <fpage>2603</fpage>
                  <lpage>2615</lpage>
                  <pub-id pub-id-type="pmid">33301246</pub-id>
                </element-citation>
              </ref>
              <ref id="bib26">
                <label>26</label>
                <element-citation publication-type="journal" id="sref26">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baden</surname>
                      <given-names>L.R.</given-names>
                    </name>
                    <name>
                      <surname>El Sahly</surname>
                      <given-names>H.M.</given-names>
                    </name>
                    <name>
                      <surname>Essink</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Kotloff</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Frey</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Novak</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title>
                  <source>N Engl J Med</source>
                  <volume>384</volume>
                  <issue>5</issue>
                  <year>2021</year>
                  <fpage>403</fpage>
                  <lpage>416</lpage>
                  <pub-id pub-id-type="pmid">33378609</pub-id>
                </element-citation>
              </ref>
              <ref id="bib27">
                <label>27</label>
                <element-citation publication-type="journal" id="sref27">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Voysey</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Clemens</surname>
                      <given-names>S.A.C.</given-names>
                    </name>
                    <name>
                      <surname>Madhi</surname>
                      <given-names>S.A.</given-names>
                    </name>
                    <name>
                      <surname>Weckx</surname>
                      <given-names>L.Y.</given-names>
                    </name>
                    <name>
                      <surname>Folegatti</surname>
                      <given-names>P.M.</given-names>
                    </name>
                    <name>
                      <surname>Aley</surname>
                      <given-names>P.K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title>
                  <source>Lancet</source>
                  <volume>397</volume>
                  <issue>10269</issue>
                  <year>2021</year>
                  <fpage>99</fpage>
                  <lpage>111</lpage>
                  <pub-id pub-id-type="pmid">33306989</pub-id>
                </element-citation>
              </ref>
              <ref id="bib28">
                <label>28</label>
                <element-citation publication-type="journal" id="sref28">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sadoff</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Gray</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Vandebosch</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Cárdenas</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Shukarev</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Grinsztejn</surname>
                      <given-names>B.</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19</article-title>
                  <source>N Engl J Med</source>
                  <volume>384</volume>
                  <year>2021</year>
                  <fpage>2187</fpage>
                  <lpage>2201</lpage>
                  <pub-id pub-id-type="pmid">33882225</pub-id>
                </element-citation>
              </ref>
              <ref id="bib29">
                <label>29</label>
                <element-citation publication-type="book" id="sref29">
                  <person-group person-group-type="author">
                    <collab>Novavax Inc</collab>
                  </person-group>
                  <part-title>Novavax confirms high levels of efficacy against original and variant COVID-19 strains in United Kingdom and South Africa trials</part-title>
                  <year>2021</year>
                  <comment>11 March 2021</comment>
                  <ext-link ext-link-type="uri" xlink:href="https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and-0" id="intref0075">https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and-0</ext-link>
                </element-citation>
              </ref>
              <ref id="bib30">
                <label>30</label>
                <element-citation publication-type="journal" id="sref30">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Supasa</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Dejnirattisai</surname>
                      <given-names>W.</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Mentzer</surname>
                      <given-names>A.J.</given-names>
                    </name>
                    <name>
                      <surname>Ginn</surname>
                      <given-names>H.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera</article-title>
                  <source>Cell</source>
                  <volume>184</volume>
                  <issue>8</issue>
                  <year>2021</year>
                  <fpage>2201</fpage>
                  <lpage>2211</lpage>
                  <comment>e7</comment>
                  <pub-id pub-id-type="pmid">33743891</pub-id>
                </element-citation>
              </ref>
              <ref id="bib31">
                <label>31</label>
                <element-citation publication-type="journal" id="sref31">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Casner</surname>
                      <given-names>R.G.</given-names>
                    </name>
                    <name>
                      <surname>Nair</surname>
                      <given-names>M.S.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Cerutti</surname>
                      <given-names>G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization</article-title>
                  <source>Cell Host Microbe</source>
                  <volume>29</volume>
                  <issue>5</issue>
                  <year>2021</year>
                  <fpage>747</fpage>
                  <lpage>751</lpage>
                  <pub-id pub-id-type="pmid">33887205</pub-id>
                </element-citation>
              </ref>
              <ref id="bib32">
                <label>32</label>
                <element-citation publication-type="journal" id="sref32">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhou</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Dejnirattisai</surname>
                      <given-names>W.</given-names>
                    </name>
                    <name>
                      <surname>Supasa</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Mentzer</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Ginnet</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title>
                  <source>Cell</source>
                  <volume>184</volume>
                  <issue>9</issue>
                  <year>2021</year>
                  <fpage>2348</fpage>
                  <lpage>2361</lpage>
                  <pub-id pub-id-type="pmid">33730597</pub-id>
                </element-citation>
              </ref>
              <ref id="bib33">
                <label>33</label>
                <element-citation publication-type="journal" id="sref33">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Emary</surname>
                      <given-names>K.R.W.</given-names>
                    </name>
                    <name>
                      <surname>Golubchik</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Aley</surname>
                      <given-names>P.K.</given-names>
                    </name>
                    <name>
                      <surname>Ariani</surname>
                      <given-names>C.V.</given-names>
                    </name>
                    <name>
                      <surname>Angus</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Bibi</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial</article-title>
                  <source>Lancet</source>
                  <volume>397</volume>
                  <issue>10282</issue>
                  <year>2021</year>
                  <fpage>1351</fpage>
                  <lpage>1362</lpage>
                  <pub-id pub-id-type="pmid">33798499</pub-id>
                </element-citation>
              </ref>
              <ref id="bib34">
                <label>34</label>
                <element-citation publication-type="book" id="sref34">
                  <person-group person-group-type="author">
                    <collab>University of Oxford</collab>
                  </person-group>
                  <part-title>ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.research.ox.ac.uk/Article/2021-02-07-chadox1-ncov-19-minimal-protection-against-mild-covid-19-from-b-1-351-variant-in-young-sa-adults" id="intref0080">https://www.research.ox.ac.uk/Article/2021-02-07-chadox1-ncov-19-minimal-protection-against-mild-covid-19-from-b-1-351-variant-in-young-sa-adults</ext-link>
                </element-citation>
              </ref>
              <ref id="bib35">
                <label>35</label>
                <element-citation publication-type="journal" id="sref35">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Heath</surname>
                      <given-names>P.T.</given-names>
                    </name>
                    <name>
                      <surname>Galiza</surname>
                      <given-names>E.P.</given-names>
                    </name>
                    <name>
                      <surname>Baxter</surname>
                      <given-names>D.N.</given-names>
                    </name>
                    <name>
                      <surname>Boffito</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Browne</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Burns</surname>
                      <given-names>F.</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.1.7 variant</article-title>
                  <source>N Engl J Med</source>
                  <year>2021 Jun 30</year>
                  <object-id pub-id-type="publisher-id">NEJMoa2107659</object-id>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2107659</pub-id>
                </element-citation>
              </ref>
              <ref id="bib36">
                <label>36</label>
                <element-citation publication-type="journal" id="sref36">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shinde</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Bhikha</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hoosain</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Archary</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Bhorat</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <name>
                      <surname>Fairlie</surname>
                      <given-names>L.</given-names>
                    </name>
                  </person-group>
                  <article-title>Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant</article-title>
                  <source>N Engl J Med</source>
                  <volume>384</volume>
                  <issue>20</issue>
                  <year>2021</year>
                  <fpage>1899</fpage>
                  <lpage>1909</lpage>
                  <pub-id pub-id-type="pmid">33951374</pub-id>
                </element-citation>
              </ref>
              <ref id="bib37">
                <label>37</label>
                <element-citation publication-type="journal" id="sref37">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Abu-Raddad</surname>
                      <given-names>L.J.</given-names>
                    </name>
                    <name>
                      <surname>Chemaitelly</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Butt</surname>
                      <given-names>A.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants</article-title>
                  <source>N Engl J Med</source>
                  <volume>385</volume>
                  <year>2021</year>
                  <fpage>187</fpage>
                  <lpage>189</lpage>
                  <pub-id pub-id-type="pmid">33951357</pub-id>
                </element-citation>
              </ref>
              <ref id="bib38">
                <label>38</label>
                <element-citation publication-type="journal" id="sref38">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Nair</surname>
                      <given-names>M.S.</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Iketani</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Luo</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Guo</surname>
                      <given-names>Y.</given-names>
                    </name>
                  </person-group>
                  <article-title>Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7</article-title>
                  <source>Nature</source>
                  <volume>593</volume>
                  <issue>7857</issue>
                  <year>2021</year>
                  <fpage>130</fpage>
                  <lpage>135</lpage>
                  <pub-id pub-id-type="pmid">33684923</pub-id>
                </element-citation>
              </ref>
              <ref id="bib39">
                <label>39</label>
                <element-citation publication-type="journal" id="sref39">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hansen</surname>
                      <given-names>C.H.</given-names>
                    </name>
                    <name>
                      <surname>Michlmayr</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Gubbels</surname>
                      <given-names>S.M.</given-names>
                    </name>
                    <name>
                      <surname>Mølbak</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Ethelberg</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study</article-title>
                  <source>Lancet</source>
                  <volume>397</volume>
                  <issue>10280</issue>
                  <year>2021</year>
                  <fpage>1204</fpage>
                  <lpage>1212</lpage>
                  <pub-id pub-id-type="pmid">33743221</pub-id>
                </element-citation>
              </ref>
              <ref id="bib40">
                <label>40</label>
                <element-citation publication-type="book" id="sref40">
                  <person-group person-group-type="author">
                    <collab>Centers for Disease Control and Prevention</collab>
                  </person-group>
                  <part-title>COVID-19 breakthrough case investigations and reporting</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html" id="intref0085">https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html</ext-link>
                </element-citation>
              </ref>
              <ref id="bib41">
                <label>41</label>
                <element-citation publication-type="journal" id="sref41">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sanders</surname>
                      <given-names>R.W.</given-names>
                    </name>
                    <name>
                      <surname>de Jong</surname>
                      <given-names>M.D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Pandemic moves and countermoves: vaccines and viral variants</article-title>
                  <source>Lancet</source>
                  <volume>397</volume>
                  <issue>10282</issue>
                  <year>2021</year>
                  <fpage>1326</fpage>
                  <lpage>1327</lpage>
                  <pub-id pub-id-type="pmid">33798497</pub-id>
                </element-citation>
              </ref>
              <ref id="bib42">
                <label>42</label>
                <element-citation publication-type="journal" id="sref42">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Callaway</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Ledford</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>How to redesign COVID vaccines so they protect against variants</article-title>
                  <source>Nature</source>
                  <volume>590</volume>
                  <issue>7844</issue>
                  <year>2021</year>
                  <fpage>15</fpage>
                  <lpage>16</lpage>
                  <pub-id pub-id-type="pmid">33514888</pub-id>
                </element-citation>
              </ref>
              <ref id="bib43">
                <label>43</label>
                <element-citation publication-type="journal" id="sref43">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bian</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Gao</surname>
                      <given-names>F.</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>He</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <name>
                      <surname>Mao</surname>
                      <given-names>Q.</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies</article-title>
                  <source>Expet Rev Vaccine</source>
                  <year>2021</year>
                  <fpage>1</fpage>
                  <lpage>9</lpage>
                </element-citation>
              </ref>
              <ref id="bib44">
                <label>44</label>
                <element-citation publication-type="journal" id="sref44">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Aldibasi</surname>
                      <given-names>O.S.</given-names>
                    </name>
                    <name>
                      <surname>Alharbi</surname>
                      <given-names>N.K.</given-names>
                    </name>
                    <name>
                      <surname>Alkelya</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Zowawi</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Alghnam</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>The association of country-level factors with outcomes of COVID-19: analysis of the pandemic after one million cases</article-title>
                  <source>Res Square</source>
                  <year>2020</year>
                </element-citation>
              </ref>
              <ref id="bib45">
                <label>45</label>
                <element-citation publication-type="journal" id="sref45">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Burden</surname>
                      <given-names>S.J.</given-names>
                    </name>
                    <name>
                      <surname>Rademaker</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Weedon</surname>
                      <given-names>B.D.</given-names>
                    </name>
                    <name>
                      <surname>Whaymand</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Dawes</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Associations of global country profiles and modifiable risk factors with COVID-19 cases and deaths</article-title>
                  <source>medRxiv</source>
                  <year>2020</year>
                  <comment>2020.06.17.20133454</comment>
                </element-citation>
              </ref>
              <ref id="bib46">
                <label>46</label>
                <element-citation publication-type="journal" id="sref46">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sorci</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Faivre</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Morand</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Explaining among-country variation in COVID-19 case fatality rate</article-title>
                  <source>Sci Rep</source>
                  <volume>10</volume>
                  <year>2020</year>
                  <fpage>18909</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41598-020-75848-2</pub-id>
                  <pub-id pub-id-type="pmid">33144595</pub-id>
                </element-citation>
              </ref>
              <ref id="bib47">
                <label>47</label>
                <element-citation publication-type="journal" id="sref47">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Garcia de Alcaniz</surname>
                      <given-names>J.G.</given-names>
                    </name>
                    <name>
                      <surname>Romero-Lopez</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Martinez</surname>
                      <given-names>R.P.</given-names>
                    </name>
                    <name>
                      <surname>Lopez-Rodas</surname>
                      <given-names>V.</given-names>
                    </name>
                    <name>
                      <surname>Costas</surname>
                      <given-names>E.</given-names>
                    </name>
                  </person-group>
                  <article-title>What variables can better predict the number of infections and deaths worldwide by SARS-CoV-2? Variation through time</article-title>
                  <source>medRxiv</source>
                  <year>2020</year>
                  <comment>2020.06.04.20122176</comment>
                </element-citation>
              </ref>
              <ref id="bib48">
                <label>48</label>
                <element-citation publication-type="journal" id="sref48">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Woody</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Tec</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Dahan</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Gaither</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Lachmann</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Fox</surname>
                      <given-names>S.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Projections for first-wave COVID-19 deaths across the US using social-distancing measures derived from mobile phones</article-title>
                  <source>medRxiv</source>
                  <year>2020</year>
                  <fpage>2020</fpage>
                  <comment>04.16.20068163</comment>
                </element-citation>
              </ref>
              <ref id="bib49">
                <label>49</label>
                <element-citation publication-type="journal" id="sref49">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Courtemanche</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Garuccio</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Le</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Pinkston</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Yelowitz</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Strong social distancing measures in the United States reduced the COVID-19 growth rate</article-title>
                  <source>Health Affairs</source>
                  <volume>39</volume>
                  <issue>7</issue>
                  <year>2020</year>
                  <fpage>1237</fpage>
                  <lpage>1246</lpage>
                  <pub-id pub-id-type="pmid">32407171</pub-id>
                </element-citation>
              </ref>
              <ref id="bib50">
                <label>50</label>
                <element-citation publication-type="journal" id="sref50">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jabłońska</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Aballéa</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Toumi</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Factors influencing the COVID-19 daily deaths' peak across European countries</article-title>
                  <source>Public Health</source>
                  <volume>194</volume>
                  <year>2021</year>
                  <fpage>135</fpage>
                  <lpage>142</lpage>
                  <pub-id pub-id-type="pmid">33892351</pub-id>
                </element-citation>
              </ref>
              <ref id="bib51">
                <label>51</label>
                <element-citation publication-type="journal" id="sref51">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sanyaolu</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Okorie</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Marinkovic</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Patidar</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Younis</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Desai</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Comorbidity and its impact on patients with COVID-19</article-title>
                  <source>SN Compr Clin Med</source>
                  <year>2020</year>
                  <fpage>1</fpage>
                  <lpage>8</lpage>
                </element-citation>
              </ref>
              <ref id="bib52">
                <label>52</label>
                <element-citation publication-type="book" id="sref52">
                  <person-group person-group-type="author">
                    <collab>Centers for Disease Control and Prevention</collab>
                  </person-group>
                  <part-title>COVID-19: people at increased risk with certain medical conditions</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html" id="intref0090">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html</ext-link>
                </element-citation>
              </ref>
              <ref id="bib53">
                <label>53</label>
                <element-citation publication-type="journal" id="sref53">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Omar</surname>
                      <given-names>S.A.</given-names>
                    </name>
                    <name>
                      <surname>Naif</surname>
                      <given-names>K.A.</given-names>
                    </name>
                    <name>
                      <surname>Mohamed</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Hosam</surname>
                      <given-names>Z.</given-names>
                    </name>
                    <name>
                      <surname>Suliman</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>The association of country-level factors with outcomes of COVID-19: analysis of the pandemic after one million cases</article-title>
                  <source>Res Square</source>
                  <year>2021</year>
                </element-citation>
              </ref>
              <ref id="bib54">
                <label>54</label>
                <element-citation publication-type="journal" id="sref54">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hadfield</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Megill</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Bell</surname>
                      <given-names>S.M.</given-names>
                    </name>
                    <name>
                      <surname>Huddleston</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Potter</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Callender</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Nextstrain: real-time tracking of pathogen evolution</article-title>
                  <source>Bioinformatics</source>
                  <year>2018</year>
                </element-citation>
              </ref>
              <ref id="bib55">
                <label>55</label>
                <element-citation publication-type="book" id="sref55">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bedford</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Neher</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Hadfield</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Hodcroft</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Sibley</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Huddleston</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <part-title>Nextstrain - real-time tracking of pathogen evolution</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://nextstrain.org/" id="intref0095">https://nextstrain.org/</ext-link>
                </element-citation>
              </ref>
              <ref id="bib56">
                <label>56</label>
                <mixed-citation publication-type="other" id="sref56">Global Initiative on Sharing All Influenza Data (GISAID). The GISAID Initiative. <ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/" id="intref0100">https://www.gisaid.org/</ext-link>(accessed 14th March 2021).</mixed-citation>
              </ref>
              <ref id="bib57">
                <label>57</label>
                <element-citation publication-type="book" id="sref57">
                  <person-group person-group-type="author">
                    <collab>Eurostat</collab>
                  </person-group>
                  <part-title>Eurostat database</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/eurostat/data/database" id="intref0105">https://ec.europa.eu/eurostat/data/database</ext-link>
                </element-citation>
              </ref>
              <ref id="bib58">
                <label>58</label>
                <element-citation publication-type="book" id="sref58">
                  <person-group person-group-type="author">
                    <collab>National Centers for Environmental Information</collab>
                  </person-group>
                  <part-title>Global surface summary of the day</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.ncei.noaa.gov/access/search/data-search/global-summary-of-the-day" id="intref0110">https://www.ncei.noaa.gov/access/search/data-search/global-summary-of-the-day</ext-link>
                </element-citation>
              </ref>
              <ref id="bib59">
                <label>59</label>
                <element-citation publication-type="book" id="sref59">
                  <person-group person-group-type="author">
                    <collab>EUROCONTROL</collab>
                  </person-group>
                  <part-title>Aviation intelligence portal</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://ansperformance.eu/data/" id="intref0115">https://ansperformance.eu/data/</ext-link>
                </element-citation>
              </ref>
              <ref id="bib60">
                <label>60</label>
                <element-citation publication-type="book" id="sref60">
                  <person-group person-group-type="author">
                    <collab>Google</collab>
                  </person-group>
                  <part-title>COVID-19 community mobility Reports</part-title>
                  <year>2021</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.google.com/covid19/mobility/" id="intref0120">https://www.google.com/covid19/mobility/</ext-link>
                </element-citation>
              </ref>
              <ref id="bib61">
                <label>61</label>
                <element-citation publication-type="journal" id="sref61">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jabłońska</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Aballéa</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Auquier</surname>
                      <given-names>P.</given-names>
                    </name>
                    <name>
                      <surname>Toumi</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe</article-title>
                  <source>medRxiv</source>
                  <year>2021</year>
                  <comment>2021.03.25.21254289</comment>
                </element-citation>
              </ref>
              <ref id="bib62">
                <label>62</label>
                <element-citation publication-type="journal" id="sref62">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Badr</surname>
                      <given-names>H.S.</given-names>
                    </name>
                    <name>
                      <surname>Du</surname>
                      <given-names>H.</given-names>
                    </name>
                    <name>
                      <surname>Marshall</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Dong</surname>
                      <given-names>E.</given-names>
                    </name>
                    <name>
                      <surname>Squire</surname>
                      <given-names>M.M.</given-names>
                    </name>
                    <name>
                      <surname>Gardner</surname>
                      <given-names>L.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study</article-title>
                  <source>Lancet Infect Dis</source>
                  <volume>20</volume>
                  <issue>11</issue>
                  <year>2020</year>
                  <fpage>1247</fpage>
                  <lpage>1254</lpage>
                  <pub-id pub-id-type="pmid">32621869</pub-id>
                </element-citation>
              </ref>
              <ref id="bib63">
                <label>63</label>
                <element-citation publication-type="journal" id="sref63">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kerr</surname>
                      <given-names>G.H.</given-names>
                    </name>
                    <name>
                      <surname>Badr</surname>
                      <given-names>H.S.</given-names>
                    </name>
                    <name>
                      <surname>Gardner</surname>
                      <given-names>L.M.</given-names>
                    </name>
                    <name>
                      <surname>Perez-Saez</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Zaitchik</surname>
                      <given-names>B.F.</given-names>
                    </name>
                  </person-group>
                  <article-title>Associations between meteorology and COVID-19 in early studies: inconsistencies, uncertainties, and recommendations</article-title>
                  <source>One Health</source>
                  <volume>12</volume>
                  <year>2021</year>
                  <fpage>100225</fpage>
                  <pub-id pub-id-type="pmid">33585669</pub-id>
                </element-citation>
              </ref>
              <ref id="bib64">
                <label>64</label>
                <element-citation publication-type="journal" id="sref64">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Merow</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Urban</surname>
                      <given-names>M.C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Seasonality and uncertainty in global COVID-19 growth rates</article-title>
                  <source>Proc Natl Acad Sci Unit States Am</source>
                  <volume>117</volume>
                  <issue>44</issue>
                  <year>2020</year>
                  <fpage>27456</fpage>
                  <lpage>27464</lpage>
                </element-citation>
              </ref>
              <ref id="bib65">
                <label>65</label>
                <element-citation publication-type="journal" id="sref65">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Engelbrecht</surname>
                      <given-names>F.A.</given-names>
                    </name>
                    <name>
                      <surname>Scholes</surname>
                      <given-names>R.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Test for Covid-19 seasonality and the risk of second waves</article-title>
                  <source>One Health</source>
                  <volume>12</volume>
                  <year>2021</year>
                  <fpage>100202</fpage>
                  <pub-id pub-id-type="pmid">33283035</pub-id>
                </element-citation>
              </ref>
              <ref id="bib66">
                <label>66</label>
                <element-citation publication-type="journal" id="sref66">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>X.</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>C.</given-names>
                    </name>
                    <name>
                      <surname>Zhao</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>Z.</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of seasonality in the spread of COVID-19 pandemic</article-title>
                  <source>Environ Res</source>
                  <volume>195</volume>
                  <year>2021</year>
                  <fpage>110874</fpage>
                  <pub-id pub-id-type="pmid">33610582</pub-id>
                </element-citation>
              </ref>
              <ref id="bib67">
                <label>67</label>
                <element-citation publication-type="journal" id="sref67">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Audi</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>AlIbrahim</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Kaddoura</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Hijazi</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Yassine</surname>
                      <given-names>H.M.</given-names>
                    </name>
                    <name>
                      <surname>Zaraket</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Seasonality of respiratory viral infections: will COVID-19 follow suit?</article-title>
                  <source>Front Public Health</source>
                  <volume>8</volume>
                  <issue>576</issue>
                  <year>2020</year>
                </element-citation>
              </ref>
              <ref id="bib68">
                <label>68</label>
                <element-citation publication-type="journal" id="sref68">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moriyama</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Hugentobler</surname>
                      <given-names>W.J.</given-names>
                    </name>
                    <name>
                      <surname>Iwasaki</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Seasonality of respiratory viral infections</article-title>
                  <source>Annu Rev Virol</source>
                  <volume>7</volume>
                  <issue>1</issue>
                  <year>2020</year>
                  <fpage>83</fpage>
                  <lpage>101</lpage>
                  <pub-id pub-id-type="pmid">32196426</pub-id>
                </element-citation>
              </ref>
              <ref id="bib69">
                <label>69</label>
                <element-citation publication-type="journal" id="sref69">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Martinez</surname>
                      <given-names>M.E.</given-names>
                    </name>
                  </person-group>
                  <article-title>The calendar of epidemics: seasonal cycles of infectious diseases</article-title>
                  <source>PLoS Pathog</source>
                  <volume>14</volume>
                  <issue>11</issue>
                  <year>2018</year>
                  <object-id pub-id-type="publisher-id">e1007327</object-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="appsec1" sec-type="supplementary-material">
              <label>Appendix A</label>
              <title>Supplementary data</title>
              <p id="p0185">The following is/are the supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.docx"><alt-text>Multimedia component 1</alt-text></media></supplementary-material>
</p>
            </sec>
            <fn-group>
              <fn id="appsec2" fn-type="supplementary-material">
                <label>Appendix A</label>
                <p id="p0190">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.puhe.2021.07.037" id="intref0010">https://doi.org/10.1016/j.puhe.2021.07.037</ext-link>.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
